Abstract
Identifying effective treatment combinations for MS patients failing standard therapy is an important goal. We report the results of a phase II open label baseline-to-treatment trial of a humanized monoclonal antibody against CD25 (daclizumab) in 10 multiple sclerosis patients with incomplete response to IFN-beta therapy and high brain inflammatory and clinical disease activity. Daclizumab was very well tolerated and led to a 78% reduction in new contrast-enhancing lesions and to a significant improvement in several clinical outcome measures.
Publication types
-
Clinical Trial
-
Clinical Trial, Phase II
-
Research Support, U.S. Gov't, P.H.S.
MeSH terms
-
Adult
-
Antibodies, Monoclonal / therapeutic use*
-
Antibodies, Monoclonal, Humanized
-
Daclizumab
-
Female
-
Humans
-
Immunoglobulin G / therapeutic use*
-
Interferon Type I / therapeutic use
-
Magnetic Resonance Imaging
-
Male
-
Middle Aged
-
Multiple Sclerosis / drug therapy
-
Multiple Sclerosis / therapy*
-
Multiple Sclerosis, Chronic Progressive / drug therapy
-
Multiple Sclerosis, Chronic Progressive / pathology
-
Multiple Sclerosis, Chronic Progressive / physiopathology
-
Multiple Sclerosis, Chronic Progressive / therapy
-
Multiple Sclerosis, Relapsing-Remitting / drug therapy
-
Multiple Sclerosis, Relapsing-Remitting / pathology
-
Multiple Sclerosis, Relapsing-Remitting / physiopathology
-
Multiple Sclerosis, Relapsing-Remitting / therapy
-
Recombinant Proteins
Substances
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Humanized
-
Immunoglobulin G
-
Interferon Type I
-
Recombinant Proteins
-
Daclizumab